|
1) Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126: 663-76
|
|
|
|
2) Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131: 861-72
|
|
|
|
|
|
3) Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007; 318: 1917-20
|
|
|
|
|
|
4) Yamashita J, Itoh H, Hirashima M, et al. Flk1 positive cells derived from embryonic stem cells serve as vascular progenitors. Nature. 2000; 408: 92-6
|
|
|
|
|
|
5) Yamashita JK, Takano M, Hiraoka-Kanie M, et al. Prospective identification of cardiac progenitor potentials by a novel single cell-based cardiomyocyte induction. FASEB J. 2005; 19: 1534-6
|
|
|
|
|
|
6) Yurugi-Kobayashi T, Itoh H, Schroeder T, et al. Adrenomedullin/cyclic AMP pathway induces Notch activation and differentiation of arterial endothelial cells from vascular progenitors. Arterioscler Thromb Vasc Biol. 2006; 26: 1977-84
|
|
|
|
|
|
7) Kono T, Kubo H, Shimazu C, et al. Differentiation of lymphatic endothelial cells from embryonic stem cells on OP9 stromal cells. Arterioscler Thromb Vasc Biol. 2006; 26: 2070-6
|
|
|
|
|
|
8) Sone M, Itoh H, Yamahara K, et al. Pathway for differentiation of human embryonic stem cells to vascular cell components and their potential for vascular regeneration. Arterioscler Thromb Vasc Biol. 2007; 27: 2127-34
|
|
|
|
|
|
9) Yamahara K, Sone M, Itoh H, et al. Augmentation of neovascularizaiton in hindlimb ischemia by combined transplantation of human embryonic stem cells-derived endothelial and mural cells. PLoS One. 2008; 3: e1666
|
|
|
|
|
|
10) Narazaki G, Uosaki M, Teranishi M, et al. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation. 2008; 118: 498-506
|
|
|
|
|
|
11) Mauritz C, Schwanke K, Reppel M, et al. Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation. 2008; 118: 507-17
|
|
|
|
|
|
12) Schenke-Layland K, Rhodes KE, Angelis E, et al. Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages. Stem Cells. 2008; 26: 1537-46
|
|
|
|
|
|
13) Mummery C, Ward-van Oostwaard D, Doevendans P, et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation. 2003; 107: 2733-40
|
|
|
|
|
|
14) Laflamme MA, Chen KY, Naumova AV, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol. 2007; 25: 1015-24
|
|
|
|
|
|
15) Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell. 2007; 1: 39-49
|
|
|
|
|
|
16) Nishikawa SI, Goldstein RA, Nierras CR. The promise of human induced pluripotent stem cells for research and therapy. Nat Rev Mol Cell Biol. 2008. Epub ahead of print
|
|
|
|
|
|
17) Nakao Y, Narazaki G, Hoshino T, et al. Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg Med Chem Lett. 2008; 18: 2982-4
|
|
|
|
|
|
18) Nakagawa M, Koyanagi M, Tanabe K, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol. 2008; 26: 101-6
|
|
|
|
|